Prevention of atherothrombotic events in MI (few days until <35 days), ischaemic stroke (7 days until <6 mth) or established peripheral arterial disease; in acute coronary syndrome: Non-ST segment elevation (unstable angina or non-Q-wave MI) including patients undergoing stent placement following percutaneous coronary intervention; ST segment elevation acute MI in medically treated patients eligible for thrombolytic therapy.
Prolonged bleeding time; increased risk of bleeding from trauma, surgery, ulcers or other pathology particularly GI or IM conditions. Patients w/ genetically reduced CYP2C19 function. Monitor blood cell counts if hematologic or bleeding disorders are suspected. Discontinue use 5-7 days prior to elective surgery or CABG. Concomitant use w/ aspirin, other NSAIDs. Bleeding diatheses in patients w/ severe hepatic disease. Severe hepatic disease, severe renal impairment (CrCl 5-15 mL/min). Pregnancy & lactation.
Sign Out
